What does Akebia Therapeutics do?
Sommario
- What does Akebia Therapeutics do?
- How many employees does Akebia Therapeutics have?
- Who makes vadadustat?
- Is akebia a buy?
- Who bought keryx?
- Does Vadadustat get approved?
- Will Vadadustat get FDA approval?
- Will Akebia Therapeutics stock go up?
- Is Akebia Therapeutics a good stock?
- How do I run keryx?
- What does Akebia do?
- What to expect from Akebia Therapeutics' (Akba) earnings call?
- Where can I find information about aakebia's inno2vate global Phase 3 program?
What does Akebia Therapeutics do?
We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.
How many employees does Akebia Therapeutics have?
Company Growth (employees)
| Employees (est.) (Dec 2018) | 324 | (+187%) |
|---|---|---|
| Website Visits (Aug 2021) | 5.4 k | |
| Revenue (FY, 2020) | $295.3 M | (-11%) |
| Share Price (Dec 2021) | $2.5 | (-1%) |
| Cybersecurity rating | B | More |
Who makes vadadustat?
Within Japan, vadadustat is approved and marketed by Mitsubishi Tanabe Pharma Corporation under the trade name VAFSEO™ as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
Is akebia a buy?
Akebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.
Who bought keryx?
Akebia Therapeutics Kidney disease specialist Akebia Therapeutics will merge with Boston-based Keryx Biopharmaceuticals in an all-stock deal, creating a $1 billion company that blends Keryx's small commercial presence on the renal market with Akebia's development pipeline.
Does Vadadustat get approved?
Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW).
Will Vadadustat get FDA approval?
Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW).
Will Akebia Therapeutics stock go up?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for Akebia Therapeutics Inc have a median target of 6.50, with a high estimate of 10.00 and a low estimate of 6.00. The median estimate represents a +155.91% increase from the last price of 2.54.
Is Akebia Therapeutics a good stock?
- Hold. Zacks' proprietary data indicates that Akebia Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the AKBA shares relative to the market in the next few months. ... The financial health and growth prospects of AKBA, demonstrate its potential to underperform the market.
How do I run keryx?
1 Answer
- Download keryx portable.
- Extract the Downloaded file.
- goto ../Downloads/keryx_1.0-public21_portable/bin.
- Double click on keryx.py and choose run/run in terminal.
What does Akebia do?
- Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the ti
What to expect from Akebia Therapeutics' (Akba) earnings call?
- AKBA earnings call for the period ending J. Shares of Akebia Therapeutics (NASDAQ: AKBA) were soaring 13.5% as of 3:32 p.m. EDT on Thursday. This result was down sharply from $90.1 million in the prior-year period due mainly to lower collaboration revenue but it was in line with the consensus estimate.
Where can I find information about aakebia's inno2vate global Phase 3 program?
- Additional information is available here: https://ir.akebia.com/news-releases/news-release-details/akebia-presents-results-its-inno2vate-global-phase-3-program. We also announced results from the PRO2TECT program for vadadustat in adult patients not on dialysis.
